Imagine using a high-tech 3D map of your heart to decide exactly where a surgeon needs to work, rather than guessing and exploring during surgery. This project creates a smart system that reads CT scans automatically to find blockages with high precision. It acts like a digital gatekeeper, ensuring only patients who truly need an invasive procedure get one.
60% of coronary artery disease patients undergo invasive angiography unnecessarily due to low diagnostic sensitivity. This creates massive hospital inefficiency and exposes patients to avoidable risks.
A vendor-agnostic, AI-powered CCTA workflow including automated stenosis algorithms and a standardized scan protocol for chronic CAD patients.
If you are a scanner manufacturer dealing with low software differentiation — this project developed AI-powered CCTA algorithms that enable definitive ischemia diagnosis. This allows your hardware to provide a complete end-to-end clinical workflow for chronic CAD patients.
If you are a software provider dealing with the need for vendor-agnostic tools — this project developed automated stenosis algorithms for coronary analysis. This allows your software to integrate into various hospital environments regardless of the scanner brand.
If you are a hospital group dealing with the fact that 60% of CAD patients unnecessarily undergo an ICA — this project developed a CCTA-enabled workflow. This reduces wasted Cath lab time and improves overall hospital efficiency.
Based on available project data, no specific pricing or cost-per-unit information is provided.
The project is developing a vendor-agnostic workflow and conducting five multicentre clinical trials to ensure the tools are scalable across different hospital sites.
Based on available project data, the coordinator is Philips Medical Systems, but specific licensing terms are not detailed in the report.
The project focuses on closing gaps in the CAD workflow by integrating CCTA data directly into the Cath lab for live guidance during procedures.
The project period runs from 2023-11-01 to 2027-10-31, suggesting a deployment window toward the end of 2027.
The consortium is heavily industry-led, with 5 industrial partners (including Philips as coordinator) representing a 36% industry ratio. This strong commercial presence, combined with 2 universities and 4 research centers across 6 countries, indicates a high focus on commercial viability and clinical translation rather than pure academic research.
Contact Philips Medical Systems Nederland BV regarding the COMBINE-CT workflow
Contact us to find licensing opportunities for AI-powered CCTA algorithms.
